Mental well-being

PreclinicalBiologic

WWageningen University

Mental well-being is one of 50 biologic programs targeting Myocardial Infarction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

87 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Praluent

Regeneron

Approved

1 2

Crestor

AstraZeneca

Approved

1 3

Neoral

Adenocard

Niacor

Kengreal

2 7

Alka-Seltzer

AAbbott

Approved

1 8

Coreg

Akero Therapeutics

Approved

1 9

Reglan

IIstituto Clinico Humanitas

Approved

1 10

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2040

Active, not recruiting

Cardiovascular Diseases

NCT03192410

Clinical

Trials by Indication[1]

Cardiovascular Diseases1 trial

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Active, not recruiting·WWageningen University··NCT03192410·4,837 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mental well-being. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mental well-being compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mental well-being. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wageningen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: WWageningen University

Mental well-being

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2040

Trials by Indication[1]

Cardiovascular Diseases1 trial

References

Drug Info

Quick Facts

Related News